Company Overview of Sequella, Inc.
Sequella, Inc., a clinical stage biopharmaceutical company, develops and commercializes treatment products for diagnosis and treatment of infectious diseases. The company’s products include TB Patch, a point-of-care diagnostic used to diagnose active tuberculosis (TB) infection; SQ109, a molecule anti-TB drug; drug compliance monitor, a medical device that records when medication is taken; SQ609, an antibiotic compound for vitro and in vivo anti-TB activities; and SQ641, a natural product for the treatment of TB or bacterial pneumonia. Sequella, Inc. was founded in 1997 and is based in Rockville, Maryland.
9610 Medical Center Drive
Rockville, MD 20850
Founded in 1997
Key Executives for Sequella, Inc.
Similar Private Companies By Industry
|Centrose LLC||United States|
|Nanotronics, Inc.||United States|
|Immunotherapy Worldwide||United States|
|Glycoregimmune, Inc.||United States|
|Adult Stem Cell Corporation of America, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Sequella, Inc., please visit www.sequella.com. Company data is provided by Capital IQ. Please use this form to report any data issues.